Largest Survey of Its Kind Finds That People With Psoriasis Are at Risk for Other Medical Conditions
Foundation data show more than half of those with psoriasis
have other health issues
PORTLAND, Ore., ... -- Emerging research reveals that people with psoriasis
are at risk for developing other serious medical ...
Winners of the Addressing Psoriasis(TM) Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim Gunn
... recognizes people with moderate to severe plaque psoriasis
who have tried not to allow the condition to ... campaign designed to help people with plaque psoriasis
get more information about managing their disease ... hundreds of people with moderate to severe plaque psoriasis
have submitted video testimonials or personal ...
Psoriasis Cure Now Welcomes Institute of Medicine Report Urging 'Comparative Effectiveness' Research on Psoriasis, But Worries About Risk of Rationing
... the Institute of Medicine (IOM) for including psoriasis
and psoriatic arthritis among its Top 100 health ... the effectiveness of various treatments for psoriasis
among its Second Quartile priorities. According ... the IOM committee for including treatments for psoriasis
and psoriatic arthritis among its priority ...
New Source of Information on Psoriasis Medications
... NeedyMeds.org and the National psoriasis
Foundation announce a new source of information on psoriasis
medications and the financial help available for ... page to its Web site tailored for those with psoriasis
. The page is a psoriasis-specific source of help ...
Psoriasis Raises Risk of Heart Attack, Stroke, Death
... MONDAY, June 15 (HealthDay News) -- People with psoriasis
face an increased risk of major cardiovascular ... disease (blockage of arteries in the legs) in the psoriasis
The overall death rate for those with psoriasis
was 86 percent higher than for those without the ...
American Academy of Dermatology Issues New Guidelines For the Management of Psoriasis With Systemic Medications
... an extensive review of scientific literature on psoriasis
and the opinion of recognized psoriasis
experts, the American Academy of Dermatology ... of care for the management and treatment of psoriasis
with traditional systemic therapies. ...
FDA Extends Review Timeline for STELARA(TM) (ustekinumab) Biologic License Application by Three Months
... of adult patients with moderate to severe plaque psoriasis
who are candidates for phototherapy or systemic ... product labeling is ongoing.
is a chronic, immune-mediated disease that ...
Psoriasis Patients Happy With Home-Based Treatment
... -- Home-based ultraviolet B (UVB) therapy for psoriasis
is as effective and safe as outpatient ... University Medical Center Utrecht looked at 196 psoriasis
patients who were randomly selected to use a UVB ... concluded.
The National psoriasis
Foundation has more about ...
Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical(TM) (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis
... Ointment, Satisfying an Unmet Need Among psoriasis
FORT WORTH, Texas, April 30 ... percent (47.1 percent) reported an improvement in psoriasis
symptoms over the course of the 52-week trial.
... patients reported a noticeable improvement in psoriasis
symptoms from baseline at week 26 (52.6 ...
SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
... with inflamed, scaly, red patches of skin psoriasis
and nail psoriasis. According to the National psoriasis
Foundation, up to 30 percent of people with psoriasis
also develop psoriatic arthritis. For additional ...
Having Psoriasis Raises Risk of Diabetes, Hypertension
Previous research had indicated that psoriasis
is associated with a higher risk of other ... diabetes at the start of the study.
Women with psoriasis
turned out to have a 63 percent increased risk of ... stated. So could the use of steroids to treat psoriasis
although, they pointed out, this course of ...
Psoriasis Drug Raptiva Pulled From U.S. Market
... April 8 (HealthDay News) -- The troubled psoriasis
drug Raptiva is being withdrawn from the U.S. ... medical officer. "Although we believe that many psoriasis
patients are benefiting from Raptiva, the balance between benefit and risk in the psoriasis
population for which Raptiva was approved has ...
Experts turn to Web to combat distressing skin disease
... People experiencing the skin disease psoriasis
may get relief from their symptoms and the ... with coping."
The eTIPS study, funded by the psoriasis
Research Trust and supported by the psoriasis
and Psoriatic Arthritis Alliance (PAPPAA), will ...
Low-Dose Acitretin May Reduce Nail Psoriasis
... Low-dose treatment with a drug used to treat skin psoriasis
seems to help reduce nail psoriasis, according to ...
As many as 78 percent of people with psoriasis
have nail psoriasis, which includes irregular ... at least six months after treatment, and the Nail psoriasis
Severity Index (NAPSI) was used to grade the ...
LeAnn Rimes Shares Her Personal Struggle With Psoriasis in Nation's Capital
"I was first diagnosed with psoriasis
at age 2 and throughout my childhood, my ... the negative effects of psoriasis."
is the most prevalent autoimmune disease in the ... affecting as many as 7.5 million Americans. psoriasis
is a noncontagious, chronic, inflammatory, ...
Study Shows Nonprescription LCD Topical Solution is More Effective than Prescription-Strength Calcipotriol Cream for Moderate Plaque Psoriasis
... outperformed calcipotriol cream for control of psoriasis
symptoms," said Alexa Kimball, MD, MPH, a CURTIS ... produced a significantly better reduction in psoriasis
severity than calcipotriol therapy in 12 weeks ... patients reported better control of a range of psoriasis
symptoms -- including scaling/flaking, redness, ...
American Academy of Dermatology Issues New Guidelines For The Management of Psoriasis With Topical Therapies
... topical agents for patients with mild to moderate psoriasis
SCHAUMBURG, Ill., March 2 ... of care for the management and treatment of psoriasis
with topical therapies based on an extensive ... on the subject and recommendations of recognized psoriasis
experts. This is the Academy's third of six ...
FDA Warns Users on Psoriasis Drug
... issued a public health advisory Thursday for the psoriasis
drug Raptiva after confirming that three people ... Bebo Jr., director of research for the National psoriasis
Foundation in Portland, Ore. "The risk to folks ... [and similar drugs] have very profound efficacy. psoriasis
is a life-changing disease for many people, and a ...
Drug Reduces Inflammatory Arthritis Symptoms, Lesions
... of those in Group 2. Of the 124 patients with psoriasis
affecting 3 percent or more body surface area, 33 ... 2 had a 75 percent or greater improvement in psoriasis
area and severity index score at week 12 of the ... editorial.
The National psoriasis
Foundation has more about psoriatric arthritis . ...
Psoriasis Cure Now launches StimulateResearch.com to Ensure That Medical Research is Part of Stimulus Bill
... politics," said Michael Paranzino, president of psoriasis
Cure Now. "It seems to have caught the patient ... wasted now will not cure cancer, arthritis or psoriasis
tomorrow. Our Web site lets Americans concerned ... states being held up by a lack of funding.
Cure Now takes no position on whether the ...
Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
... for the
treatment of mild-to-moderate plaque psoriasis
is a chronic skin disorder that affects 2 to 3 ... on
sensitive skin fold areas.
is a chronic disease, topical products that are ...
Gene Insights May Improve Psoriasis Care
... The team looked for DNA changes in thousands of psoriasis
patients and healthy people, and identified seven ... IL-213 pathway are already targeted by effective psoriasis
therapies. Others, like the TNFAIP3 and TNIP1, may become targets for the psoriasis
treatments of the future," co-principal ...
Scientists unmask genetic markers associated with psoriasis
... IL-23 pathway are already targeted by effective psoriasis
therapies. Others, like TNFAIP3 and TNIP1, may become targets for the psoriasis
treatments of the future."
affects some 7.5 million people in the United ...
An Oral Agent for the Treatment of Moderate to Severe Psoriasis Would Earn a Higher Patient Share in the United States than in Europe
... Decision Resources' Clinical Gold-Standard for psoriasis
in 2012, According to a New Report from Decision ... agent for the treatment of moderate to severe psoriasis
that demonstrates improved efficacy and lasting ... the performance of biological agents in the psoriasis
market, oral therapies are still preferred by ...
Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings
... opportunities include:
-- Launched in Europe and the U.S. in 2008.
-- RA Japan -- Launched in 2008.
Japan -- Indication filed, under regulatory ... promising results in early studies for psoriasis
also being explored as a treatment ...
Obesity-Related Hormone Tied to Psoriasis
... MONDAY, Dec. 15 (HealthDay News) -- People with psoriasis
have higher levels of the obesity-related hormone ... shows.
The Taiwanese study included 77 psoriasis
patients and a control group of 81 people without ... role in immune and inflammatory processes.
patients were more likely than those in the ...
Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
... Percentage of Biologic-Treated psoriasis
Patients Will Double by 2017, According to a New ... Humira, will drive the moderate to severe psoriasis
drug market to more than double to nearly $5 ...
The new Pharmacor report entitled psoriasis
finds that the ...
Indigo Ointment Benefits Psoriasis Patients
... They studied 42 people with treatment-resistant psoriasis
who were treated with an ointment made from ... who completed the study experienced worsening psoriasis
in the areas treated with the indigo ointment, ... Academy of Family Physicians has more about psoriasis
-- Robert ...
National Psoriasis Foundation Seeks 10,000 Americans to Support Psoriasis Research for World Psoriasis Day
... -- For World Psoriasis
Day, Oct. 29, the National psoriasis
Foundation wants 10,000 Americans to
visit its ... on the skin.
During the fifth annual World psoriasis
Day, awareness activities will
occur all over the ... access to
treatments and build unity among the psoriasis
and psoriatic arthritis
"Over the ...
National Psoriasis Foundation Releases 2008 Study Results
is a significant problem in daily life, survey ... of people living with psoriasis
say the disease is a
significant problem in daily ... today.
The survey of 426 individuals with psoriasis
and psoriatic arthritis
also revealed that their ...
After Fits and Starts, New Hope for Psoriasis Patients
... Doctors tout drugs called biologics during psoriasis
MONDAY, Aug. 25 (HealthDay News) -- psoriasis
can be a maddening disease.
Patches of thick, ... the worse the person suffers.
And because psoriasis
is a genetic condition that causes inflammation ...
Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
... with inflamed, scaly, red patches
of skin psoriasis
nail involvement. Symptoms may include
stiffness ... feet, lower
back and neck are commonly affected. psoriasis
affects an estimated two to
three percent of the ...
FDA Panel Recommends Enbrel for Pediatric Patients
... But experts also express concern about psoriasis
drug's possible risks for children; action ... advisory panel recommended Wednesday that the psoriasis
drug Enbrel be approved for use in children who ... rheumatoid arthritis in adults and children, and psoriasis
in adults only.
The agency staff said Monday ...
Dermatologists Release Psoriasis Care Guidelines
... guidelines for the management of mild to severe psoriasis
and psoriatic arthritis released by the American ... that pinpoint immune responses involved with psoriasis
and psoriatic arthritis.
About 6 million to 7 ... in a prepared statement.
"The guidelines for psoriasis
and psoriatic arthritis, which focus on the use ...
American Academy of Dermatology Issues New Guidelines for the Management of Psoriasis and Psoriatic Arthritis
... new guidelines of care for the
management of psoriasis
and psoriatic arthritis based on an ... of the American Academy of
Dermatology, the new psoriasis
and psoriatic guidelines present the ... president of the Academy. "The
guidelines for psoriasis
and psoriatic arthritis, which focus on the use ...
Drug Works Well for Moderate-to-Severe Psoriasis
... and long-term treatment for moderate-to-severe psoriasis
in two studies published in this week's issue of ... two-thirds of patients with moderate-to-severe psoriasis
achieved at least a 75 percent improvement in ... dose did much better in retaining their improved psoriasis
"Our results suggest that ...
FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
... it over the useful life of the product.
is a chronic, inflammatory skin disease for which there is no
cure. In plaque psoriasis
(psoriasis vulgaris), the most common ... silvery
white scales. A non-contagious disorder, psoriasis
can occur on any part of
the body, and can ...
New In-Depth Informative Website Launched for People With Psoriasis and Psoriatic Arthritis
... -- On the 1st of May 2008, UK
charity, the psoriasis
and Psoriatic Arthritis Alliance (PAPAA) ... banner of The
Principal Source of Information for psoriasis
and Psoriatic Arthritis.
PAPAA is providing an ... with real input from people with or affected by psoriasis
David Chandler PAPAA ...
New Psoriasis Pill Appears Effective
... A new drug for patients with moderate to severe psoriasis
appears to be safe and effective, a Canadian ... for psoriasis, the researchers said.
is an autoimmune skin disease. The most common ... one of the most effective treatments for psoriasis
is the calcineurin inhibitor drug ciclosporin. ...
Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
... five key regulatory approvals: HUMIRA for psoriasis
and for juvenile rheumatoid arthritis, ... * HUMIRA(R) Indications Approved o psoriasis
-- Abbott received FDA approval for HUMIRA to ... achieved a 75 percent reduction in psoriasis